Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of JS207 plus Platinum-Based Chemotherapy in Stage II–III NSCLC
ChiCTR2500113936Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of JS207 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Pathological complete response rate (pCR rate). Started Dec 2025; status: recruiting.
02
Drugs
JS207
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500113936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113936.